{"id":"https://openalex.org/W37749742","doi":null,"title":"Crizotinib (Xalkori\u00ae) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)","display_name":"Crizotinib (Xalkori\u00ae) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)","publication_year":2013,"publication_date":"2013-03-01","ids":{"openalex":"https://openalex.org/W37749742","mag":"37749742"},"language":"en","primary_location":{"id":"mag:37749742","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/993/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029048566","display_name":"Thomas Semlitsch","orcid":"https://orcid.org/0000-0002-1763-7855","observed_orcids":["https://orcid.org/0000-0002-1763-7855"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thomas Semlitsch","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1763-7855","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5033350628","display_name":"Klaus Jeitler","orcid":"https://orcid.org/0000-0002-1520-8061","observed_orcids":["https://orcid.org/0000-0002-1520-8061"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Klaus Jeitler","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-1520-8061","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0051535,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/crizotinib","display_name":"crizotinib","score":1.0},{"id":"https://openalex.org/keywords/anaplastic-lymphoma-kinase","display_name":"anaplastic lymphoma kinase","score":0.9570000171661377},{"id":"https://openalex.org/keywords/alk-positive-non-small-cell-lung-cancer","display_name":"ALK-positive non-small cell lung cancer","score":0.9909999966621399},{"id":"https://openalex.org/keywords/alk-fusion","display_name":"ALK fusion","score":0.7360000014305115},{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.7699999809265137},{"id":"https://openalex.org/keywords/second-line-treatment","display_name":"second-line therapy","score":0.8320000171661377},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.824999988079071},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7379999756813049},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6949999928474426},{"id":"https://openalex.org/keywords/visual-disturbances","display_name":"visual disturbances","score":0.7490000128746033},{"id":"https://openalex.org/keywords/alk-testing","display_name":"ALK testing","score":0.8420000076293945},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.9089999794960022}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.9905264377593994},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.790338397026062},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.760593056678772},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.7532389163970947},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7180195450782776},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.6574634313583374},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6544643640518188},{"id":"https://openalex.org/C2779220645","wikidata":"https://www.wikidata.org/wiki/Q21099132","display_name":"Alectinib","level":5,"score":0.5480579733848572},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4394254982471466},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4385491907596588},{"id":"https://openalex.org/C2775999482","wikidata":"https://www.wikidata.org/wiki/Q18031208","display_name":"ROS1","level":4,"score":0.4249306619167328},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3528715968132019},{"id":"https://openalex.org/C2781182431","wikidata":"https://www.wikidata.org/wiki/Q356033","display_name":"Adenocarcinoma","level":3,"score":0.25303202867507935},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:37749742","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/993/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[{"id":"https://openalex.org/G666505512","display_name":null,"funder_award_id":"P30-CA045508","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2118726443","https://openalex.org/W1965546100","https://openalex.org/W2902475867","https://openalex.org/W2257265893","https://openalex.org/W954457330","https://openalex.org/W2972079805","https://openalex.org/W2061109334","https://openalex.org/W2766602847","https://openalex.org/W2809677973","https://openalex.org/W4390562819"],"abstract_inverted_index":{"An":[0],"activating":[1],"mutation":[2],"of":[3,15,43,50,86,103,135,171,192,198,206,214,222,227,232,235,249,258,273,318],"the":[4,48,57,110,151,157,178,201,217,244,250,254,263,270,274,283],"anaplastic":[5],"lymphoma":[6],"kinase":[7],"(ALK)":[8],"fusion":[9],"gene":[10],"is":[11,66,117,303],"responsible":[12],"for":[13,47,72,150,183,305],"1-7%":[14],"non-small":[16],"lung":[17,193],"cancer":[18,194],"(NSCLC).":[19],"In":[20,62,109],"Austria":[21],"approximately":[22],"30":[23],"to":[24,68,121,174,225,266,300,321],"200":[25],"patients":[26,75,126,184,215],"will":[27],"be":[28,226,267],"newly":[29],"diagnosed":[30],"with":[31,52,76,127,186],"ALK-positive":[32,53,73,129,293],"NSCLC":[33,55,74,294],"per":[34],"year.":[35],"\nCrizotinib,":[36],"a":[37,132,139,211,296,313],"selective":[38],"adenosine":[39],"triphosphatase-competitive":[40],"small-molecule":[41],"inhibitor":[42],"ALK,":[44],"was":[45,167],"licensed":[46],"treatment":[49,301],"adults":[51],"advanced":[54,128],"in":[56,59,119,124,163,177,190,210,216,240],"U.S.":[58],"August":[60],"2011.":[61],"Europe":[63],"this":[64],"approval":[65],"restricted":[67],"second":[69],"line":[70],"therapy":[71],"disease":[77,175],"progression":[78,143,176],"after":[79],"chemotherapy":[80,123],"only.":[81],"\nTo":[82],"date,":[83],"interim":[84,247],"results":[85,248,264,272,311],"2":[87],"single":[88],"arm":[89],"Phase":[90],"II":[91],"trials":[92,105],"and":[93,146,196,256,262,276,285,312],"1":[94],"randomized":[95],"controlled":[96],"phase":[97,111],"III":[98,112],"trial":[99,113],"were":[100,154,161,188,238],"published.":[101],"All":[102],"these":[104],"are":[106,317],"still":[107],"ongoing.":[108],"(Profile":[114],"1007)":[115],"crizotinib":[116,152,179,187,218,259,290],"investigated":[118],"comparison":[120],"standard":[122],"347":[125],"NSCLC.":[130],"After":[131],"median":[133],"follow-up":[134],"about":[136],"12":[137],"months":[138],"statistically":[140],"significant":[141],"better":[142],"free":[144],"survival":[145,159],"objective":[147],"response":[148],"rate":[149],"group":[153],"reported.":[155],"Although":[156],"overall":[158],"rates":[160,231],"comparable":[162],"both":[164,241],"groups,":[165],"there":[166],"an":[168,323],"increased":[169],"number":[170],"deaths":[172],"related":[173],"group.":[180],"\nSignificant":[181],"benefits":[182],"treated":[185],"reported":[189],"terms":[191],"symptoms":[195],"quality":[197,315],"life.":[199],"On":[200],"other":[202],"hand,":[203],"different":[204],"types":[205],"vision":[207],"disorders":[208],"occurred":[209],"higher":[212,236],"proportion":[213],"group,":[219],"but":[220],"all":[221],"them":[223],"seemed":[224],"lower":[228],"grades.":[229],"The":[230],"adverse":[233],"events":[234],"grade":[237],"similar":[239],"groups.":[242],"\nDespite":[243],"seemingly":[245],"positive":[246],"Profile":[251],"1007":[252],"trial,":[253],"effectiveness":[255],"toxicity":[257],"remains":[260],"uncertain":[261],"have":[265],"confirmed":[268],"by":[269,277,282],"final":[271],"study":[275],"further":[278],"RCTs,":[279],"as":[280],"demanded":[281],"European":[284],"US":[286],"regulatory":[287],"authorities.":[288],"As":[289],"affects":[291],"only":[292],"patients,":[295],"reliable":[297,309],"ALK-testing":[298],"prior":[299],"initiation":[302],"crucial":[304],"patient":[306,325],"selection.":[307,326],"Therefore,":[308],"test":[310],"rigorous":[314],"assessment":[316],"maximum":[319],"importance":[320],"ensure":[322],"appropriate":[324]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2016-06-24T00:00:00"}